China Medical System （00867）Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer’s Type
As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
Hosted on MSN23h
Breakthrough drugs herald ‘new era’ in battle against dementia, experts predict
Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer’s Agitation “CALMA” and Expands Recruitment Strategy
POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease ...
News Medical on MSN3h
Life expectancy and nursing home admission in people with dementia
The average life expectancy of people diagnosed with dementia ranges from 9 years at age 60 to 4.5 years at age 85 for women ...
Common sleep aid may disrupt system that clears brain waste linked to Alzheimer's
Getting a good night's sleep is a critical part of our daily biological cycle and is associated with improved brain function, ...
J&J's Posdinemab Granted FDA Fast Track Designation For Alzheimer's Treatment
Johnson & Johnson (JNJ) announced that the FDA has granted Fast Track designation to its Posdinema, a monoclonal antibody ...
Johnson & Johnson Gets FDA Fast-Track Designation for Posdinemab in Alzheimer's
The New Brunswick, N.J., pharmaceutical giant said posdinemab has shown potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid from treated Alzheimer's patients, and in ...